NDRG4 Antibodies

Santa Cruz Biotechnology features a diverse variety of NDRG4 monoclonal antibodies for research in understanding NDRG4's role in various biological processes. NDRG4 Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). NDRG4, or N-Myc downstream-regulated gene 4, is implicated in cellular differentiation and has been associated with tumor suppression and neuroprotection. NDRG4 expression is often altered in various cancers, making it a significant focus for understanding tumor biology and potential therapeutic targets. Additionally, NDRG4 plays a role in the regulation of cell growth and apoptosis, highlighting its importance in maintaining cellular homeostasis. NDRG4 has emerged as a crucial biomarker in cancer research and neurological studies. Research has shown that NDRG4 expression patterns can serve as indicators for disease progression and treatment response. Understanding NDRG4's molecular mechanisms can provide insights into developing targeted therapies. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance their understanding of NDRG4's role in human health and disease.